非酒精性脂肪性肝病代谢组学与中医证候

高静静; 汪涛; 蒋元烨; 曹勤

doi:10.3969/j.issn.1001-5256.2020.08.044

非酒精性脂肪性肝病代谢组学与中医证候

DOI: 10.3969/j.issn.1001-5256.2020.08.044

上海中医药大学附属普陀医院消化内科

基金项目:

国家自然科学基金青年项目(81703879)；上海市卫计委临床研究专项面上项目(201840377,201940449)；普陀区科委自主创新项目(ptkwws201813,ptkwws201806)；上海中医药大学附属普陀医院重点专科(2016103A)；

详细信息

中图分类号: R259
计量
- 文章访问数: 848
- HTML全文浏览量: 36
- PDF下载量: 182
- 被引次数: 0
出版历程
- 出版日期: 2020-08-20

Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease

Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine

Research funding:

摘要

摘要:
非酒精性脂肪性肝病(NAFLD)发病率逐年增加,是全球范围最常见的肝病之一。代谢组学继承了基因组学、蛋白质组学的研究思想,对生物体内所有代谢物进行定量分析,探索代谢物与生理病理变化的相对关系,为研究中医药诊治NAFLD开辟了新途径。总结了代谢组学与中医证侯在NAFLD中的研究进展,为进一步探索NAFLD提供新的思路与方法。
- 非酒精性脂肪性肝病 /
- 代谢组学 /
- 证候
Abstract:
The incidence rate of nonalcoholic fatty liver disease(NAFLD) is increasing year by year and NAFLD has become one of the most common liver diseases in the world.Metabolomics follows the research thoughts of genomics and proteomics and conducts a quantitative analysis of all metabolites in organisms to explore the association between metabolites and physiological and pathological changes,which provides a new way for studying the traditional Chinese medicine diagnosis and treatment of NAFLD.This article summarizes the research advances in metabolomics and traditional Chinese medicine syndromes in NAFLD,so as to provide new thoughts and methods for further exploration of NAFLD.
- non-alcoholic fatty liver disease /
- metabolomics /
- symptom complex

HTML全文

参考文献(37)

[1] COBBINA E,AKHLAGHI F. Non-alcoholic fatty liver disease(NAFLD)-pathogenesis,classification,and effect on drug metabolizing enzymes and transporters[J]. Drug Metab Rev,2017,49(2):197-211.

[2] TU LN,SHOWALTER MR,CAJKA T,et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice[J]. Sci Rep,2017,7(1):6120.

[3] CHEN F,ESMAILI S,ROGERS GB,et al. Lean NAFLD:A distinct entity shaped by differential metabolic adaptation[J].Hepatology,2020,71(4):1213-1227.

[4] SANYAL AJ,FRIEDMAN SL,MCCULLOUGH AJ,et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis:Findings and recommendations from an American Association for the Study of Liver Diseases-U. S. Food and Drug Administration Joint Workshop[J]. Hepatology,2015,61(4):1392-1405.

[5] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.

[6] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol,2018,34(12):34-38.(in Chinese)李婕．亚洲地区非酒精性脂肪性肝病的流行病学特点[J]．临床肝胆病杂志，2018,34(12):34-38.

[7] ZHANG AH,SUN H,QIU S,et al. Recent highlights of metabolomics in Chinese medicine syndrome research[J]. Evid Based Complement Alternat Med,2013,2013:402159.

[8] EVANGELATOS N,BAUER P,REUMANN M,et al. Metabolomics in sepsis and its impact on public health[J]. Public Health Genomics,2017,20(5):274-285.

[9] LANS I,GANTNER M,MURINELLO S,et al. Metabolomics in the study of retinal health and disease[J]. Prog Retin Eye Res,2019,69:57-79.

[10] CHEN X,YU D. Metabolomics study of oral cancers[J].Metabolomics,2019,15(2):22.

[11] HYTYLINEN T. Novel methodologies in metabolic profiling with a focus on molecular diagnostic applications[J]. Expert Rev Mol Diagn,2012,12(5):527-538.

[12] NEMKOV T,REISZ JA,GEHRKE S,et al. High-throughput metabolomics:Isocratic and gradient mass spectrometrybased methods[J]. Methods Mol Biol,2019,1978:13-26.

[13] HE J. Study on mechanism of collagen-induced arthritis(CIA)rats treated with moxibustion based on urinary metabolomics[D].Nanjing:Nanjing University of Chinese Medicine,2019.(in Chinese)何静．基于尿液代谢组学艾灸治疗胶原诱导型关节炎大鼠的作用机制研究[D]．南京:南京中医药大学，2019.

[14] KHUSIAL RD,CIOFFI CE,CALTHARP SA,et al. Development of a plasma screening panel for pediatric nonalcoholic fatty liver disease using metabolomics[J]. Hepatol Commun,2019,3(10):1311-1321.

[15] LI J,ZHAO Y,HUANG C,et al. Serum metabolomic analysis of the effect of exercise on nonalcoholic fatty liver disease[J].Endocr Connect,2019,8(4):299-308.

[16] KALHAN SC,GUO L,EDMISON J,et al. Plasma metabolomic profile in nonalcoholic fatty liver disease[J]. Metabolism,2011,60(3):404-413.

[17] DONG S,ZHAN ZY,CAO HY,et al. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease[J]. World J Gastroenterol,2017,23(15):2771-2784.

[18] MICCHELI A,CAPUANI G,MARINI F,et al. Urinary(1)HNMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment[J]. Int J Obes(Lond),2015,39(7):1118-1125.

[19] VINAIXA M,RODRGUEZ MA,RULL A,et al. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease[J]. J Proteome Res,2010,9(5):2527-2538.

[20] LI ZH,ZHANG N,WANG Y,et al. Mechanism of Yinchenhao Decoction in treating non-alcoholic fatty liver based on 16S rRNA technique and metabonomics[J]. Chin J Tradit Chin Med Pharm,2019,34(5):1908-1913.(in Chinese)李自辉，张娜，王宇，等．基于16S rRNA技术与代谢组学探究茵陈蒿汤治疗非酒精性脂肪肝的作用机制[J]．中华中医药杂志，2019,34(5):1908-1913.

[21] FAN SC,GAO Y,ZHANG HZ,et al. Untargeted and targeted metabolomics and their applications in discovering drug targets[J]. Prog in Pharm Sci,2017,41(4):263-269.(in Chinese)范仕成，高悦，张慧贞，等．非靶向和靶向代谢组学在药物靶点发现中的应用[J]．药学进展，2017,41(4):263-269.

[22] JOHNSON CH,IVANISEVIC J,SIUZDAK G. Metabolomics:Beyond biomarkers and towards mechanisms[J]. Nat Rev Mol Cell Biol,2016,17(7):451-459.

[23] FELDMAN A,EDER SK,FELDER TK,et al. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver:A targeted metabolomics approach[J]. Diabetes Metab,2019,45(2):132-139.

[24] PAPANDREOU C,BULLM,TINAHONES FJ,et al. Serum metabolites in non-alcoholic fatty-liver diease development or reversion; a targeted metabolomic approach within the PREDIMED trial[J]. Nutr Metab,2017,14:58.

[25] XU Y,HAN J,DONG J,et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development[J]. Int J Mol Sci,2019,20(5):1220.

[26] ZHU H,WANG Z,WU Y,et al. Untargeted metabonomics reveals intervention effects of chicory polysaccharide in a rat model of non-alcoholic fatty liver disease[J]. Int J Biol Macromol,2019,128:363-375.

[27] SETHI S,BRIETZKE E. Recent advances in lipidomics:Analytical and clinical perspectives[J]. Prostaglandins Other Lipid Mediat,2017,128-129:8-16.

[28] YANG RX,HU CX,MI YQ,et al. A serum lipidomic study of patients with non-alcoholic fatty liver disease[J]. Chin J Hepatol,2017,25(2):122-127.(in Chinese)杨蕊旭，胡春秀，宓余强，等．非酒精性脂肪性肝病患者血清脂质组学研究[J]．中华肝脏病杂志，2017,25(2):122-127.

[29] FENG S,GAN L,YANG CS,et al. Effects of stigmasterol andβ-sitosterol on nonalcoholic fatty liver disease in a mouse model:A lipidomic analysis[J]. J Agric Food Chem,2018,66(13):3417-3425.

[30] PREUSS C,JELENIK T,BDIS K,et al. A new targeted lipidomics approach reveals lipid droplets in liver,muscle and heart as a repository for diacylglycerol and ceramide species in non-alcoholic fatty liver[J]. Cells,2019,8(3):277.

[31] WANG J,MA Q,LI Y,et al. Research progress on traditional Chinese medicine syndromes of diabetes mellius[J]. Biomed Pharmacother,2020,121:109565.

[32] GU LM,CAO PR,GU C. Correlation between traditional Chinese medicine syndrome and clinical biochmical indexes of non-alcoholic fatty liver[J]. J Nanjing Univ Tradit Chin Med,2019,35(6):738-740.(in Chinese)顾立梅，曹培让，顾超．非酒精性脂肪肝中医证型及临床生化指标相关性研究[J]．南京中医药大学学报，2019,35(6):738-740.

[33] LI ZG,JIANG HX,JIAO YT. Literary analysis on distribution of traditional Chinese medicine syndromes of non-alcoholic fatty liver disease[J]. Chin J Tradit Chin Med Pharm,2017,32(10):4713-4715.(in Chinese)李志国，姜韩雪，焦云涛．非酒精性脂肪性肝病中医证型分布的文献分析[J]．中华中医药杂志，2017,32(10):4713-4715.

[34] MA X,GU HT,ZHAO Y. Serum metabolomics study on nonalcoholic fatty liver disease with liver damage of different syndromes[J]. Chin J Tradit Chin Med Pharm,2017,32(3):1246-1250.(in Chinese)马欣，顾宏图，赵瑜．不同证候的非酒精性脂肪肝合并肝损伤患者的血清代谢组学分析[J]．中华中医药杂志，2017,32(3):1246-1250.

[35] DAI J,SUN S,CAO J,et al. Similar connotation in chronic hepatitis B and nonalcoholic fatty liver patients with dampness-heat syndrome[J]. Evid Based Complement Alternat Med,2013,2013:793820.

[36] GUAN W,LI RY,GUO JL. Analysis of mechanism of Xiaoyaowan on rats with nonalcoholic fatty liver disease and syndrome of liver depression and spleen deficiency by1H-NMR metabolomic[J].Chin J Exp Tradit Med Form,2019,24(19):99-111.(in Chinese)关伟，李若瑜，郭继龙．基于1H-NMR代谢组学技术分析逍遥丸干预非酒精性脂肪肝肝郁脾虚证大鼠的作用机制[J]．中国实验方剂学杂志，2019,24(19):99-111.

[37] LI RY,MIAO YC,LI ML. Urinary metabolomic study on liver depression and spleen deficiency syndrome of nonalcoholic fatty liver in rats[J]. Chin J Basic Med Tradit Chin Med,2019,24(19):99-111.(in Chinese)李若瑜，庙宇船，李明磊．大鼠非酒精性脂肪肝肝郁脾虚证的尿液代谢组学研究[J]．中国中医基础医学杂志，2019,24(19):99-111.

施引文献

资源附件(0)

访问统计